Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azodicarbonamide - H-Phar / Universite Libre de Bruxelles

Drug Profile

Azodicarbonamide - H-Phar / Universite Libre de Bruxelles

Alternative Names: ADA; HPH-116; NSC 674447

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Universite Libre de Bruxelles
  • Developer H-Phar; Universite Libre de Bruxelles
  • Class Amides; Antiretrovirals; Aza compounds; Small molecules
  • Mechanism of Action HIV zinc finger inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections
  • No development reported Transplant rejection

Most Recent Events

  • 09 Jul 2019 Azodicarbonamide is still in phase II trials for HIV infections in Spain(EudraCT 2007-000950-30)
  • 24 Jun 2018 Biomarkers information updated
  • 17 Aug 2015 Phase-II development is ongoing in Spain for HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top